Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection

Elderly people are at high risk for influenza-related morbidity and mortality due to progressive immunosenescence. While toll-like receptor (TLR) agonist containing adjuvants, and other adjuvants, have been shown to enhance influenza vaccine-induced protective responses, the mechanisms underlying ho...

Full description

Bibliographic Details
Main Authors: Susan L. Baldwin, Fan-Chi Hsu, Neal Van Hoeven, Emily Gage, Brian Granger, Jeffrey A. Guderian, Sasha E. Larsen, Erica C. Lorenzo, Laura Haynes, Steven G. Reed, Rhea N. Coler
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2018.00295/full
id doaj-cd54c7b7862442a1ab8188b770192449
record_format Article
spelling doaj-cd54c7b7862442a1ab8188b7701924492020-11-24T22:30:01ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-02-01910.3389/fimmu.2018.00295310700Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza InfectionSusan L. Baldwin0Fan-Chi Hsu1Neal Van Hoeven2Emily Gage3Brian Granger4Jeffrey A. Guderian5Sasha E. Larsen6Erica C. Lorenzo7Laura Haynes8Steven G. Reed9Rhea N. Coler10Rhea N. Coler11Rhea N. Coler12Infectious Disease Research Institute, Seattle, WA, United StatesInfectious Disease Research Institute, Seattle, WA, United StatesInfectious Disease Research Institute, Seattle, WA, United StatesInfectious Disease Research Institute, Seattle, WA, United StatesInfectious Disease Research Institute, Seattle, WA, United StatesInfectious Disease Research Institute, Seattle, WA, United StatesInfectious Disease Research Institute, Seattle, WA, United StatesCenter on Aging, Department of Immunology, University of Connecticut School of Medicine, Farmington, CT, United StatesCenter on Aging, Department of Immunology, University of Connecticut School of Medicine, Farmington, CT, United StatesInfectious Disease Research Institute, Seattle, WA, United StatesInfectious Disease Research Institute, Seattle, WA, United StatesDepartment of Global Health, University of Washington, Seattle, WA, United StatesPAI Life Sciences, Seattle, WA, United StatesElderly people are at high risk for influenza-related morbidity and mortality due to progressive immunosenescence. While toll-like receptor (TLR) agonist containing adjuvants, and other adjuvants, have been shown to enhance influenza vaccine-induced protective responses, the mechanisms underlying how these adjuvanted vaccines could benefit the elderly remain elusive. Here, we show that a split H1N1 influenza vaccine (sH1N1) combined with a TLR4 agonist, glucopyranosyl lipid adjuvant formulated in a stable oil-in-water emulsion (GLA-SE), boosts IgG2c:IgG1 ratios, enhances hemagglutination inhibition (HAI) titers, and increases protection in aged mice. We find that all adjuvanted sH1N1 vaccines tested were able to protect both young and aged mice from lethal A/H1N1/California/4/2009 virus challenge after two immunizations compared to vaccine alone. We show that GLA-SE combined with sH1N1, however, also provides enhanced protection from morbidity in aged mice given one immunization (based on change in weight percentage). While the GLA-SE-adjuvanted sH1N1 vaccine promotes the generation of cytokine-producing T helper 1 cells, germinal center B cells, and long-lived bone marrow plasma cells in young mice, these responses were muted in aged mice. Differential in vitro responses, dependent on age, were also observed from mouse-derived bone marrow-derived dendritic cells and lung homogenates following stimulation with adjuvants, including GLA-SE. Besides enhanced HAI titers, additional protective factors elicited with sH1N1 + GLA-SE in young mice were observed, including (a) rapid reduction of viral titers in the lung, (b) prevention of excessive lung inflammation, and (c) homeostatic maintenance of alveolar macrophages (AMs) following H1N1 infection. Collectively, our results provide insight into mechanisms of adjuvant-mediated immune protection in the young and elderly.http://journal.frontiersin.org/article/10.3389/fimmu.2018.00295/fullinfluenzavaccineadjuvantelderlyT helper 1H1N1
collection DOAJ
language English
format Article
sources DOAJ
author Susan L. Baldwin
Fan-Chi Hsu
Neal Van Hoeven
Emily Gage
Brian Granger
Jeffrey A. Guderian
Sasha E. Larsen
Erica C. Lorenzo
Laura Haynes
Steven G. Reed
Rhea N. Coler
Rhea N. Coler
Rhea N. Coler
spellingShingle Susan L. Baldwin
Fan-Chi Hsu
Neal Van Hoeven
Emily Gage
Brian Granger
Jeffrey A. Guderian
Sasha E. Larsen
Erica C. Lorenzo
Laura Haynes
Steven G. Reed
Rhea N. Coler
Rhea N. Coler
Rhea N. Coler
Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
Frontiers in Immunology
influenza
vaccine
adjuvant
elderly
T helper 1
H1N1
author_facet Susan L. Baldwin
Fan-Chi Hsu
Neal Van Hoeven
Emily Gage
Brian Granger
Jeffrey A. Guderian
Sasha E. Larsen
Erica C. Lorenzo
Laura Haynes
Steven G. Reed
Rhea N. Coler
Rhea N. Coler
Rhea N. Coler
author_sort Susan L. Baldwin
title Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
title_short Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
title_full Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
title_fullStr Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
title_full_unstemmed Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
title_sort improved immune responses in young and aged mice with adjuvanted vaccines against h1n1 influenza infection
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2018-02-01
description Elderly people are at high risk for influenza-related morbidity and mortality due to progressive immunosenescence. While toll-like receptor (TLR) agonist containing adjuvants, and other adjuvants, have been shown to enhance influenza vaccine-induced protective responses, the mechanisms underlying how these adjuvanted vaccines could benefit the elderly remain elusive. Here, we show that a split H1N1 influenza vaccine (sH1N1) combined with a TLR4 agonist, glucopyranosyl lipid adjuvant formulated in a stable oil-in-water emulsion (GLA-SE), boosts IgG2c:IgG1 ratios, enhances hemagglutination inhibition (HAI) titers, and increases protection in aged mice. We find that all adjuvanted sH1N1 vaccines tested were able to protect both young and aged mice from lethal A/H1N1/California/4/2009 virus challenge after two immunizations compared to vaccine alone. We show that GLA-SE combined with sH1N1, however, also provides enhanced protection from morbidity in aged mice given one immunization (based on change in weight percentage). While the GLA-SE-adjuvanted sH1N1 vaccine promotes the generation of cytokine-producing T helper 1 cells, germinal center B cells, and long-lived bone marrow plasma cells in young mice, these responses were muted in aged mice. Differential in vitro responses, dependent on age, were also observed from mouse-derived bone marrow-derived dendritic cells and lung homogenates following stimulation with adjuvants, including GLA-SE. Besides enhanced HAI titers, additional protective factors elicited with sH1N1 + GLA-SE in young mice were observed, including (a) rapid reduction of viral titers in the lung, (b) prevention of excessive lung inflammation, and (c) homeostatic maintenance of alveolar macrophages (AMs) following H1N1 infection. Collectively, our results provide insight into mechanisms of adjuvant-mediated immune protection in the young and elderly.
topic influenza
vaccine
adjuvant
elderly
T helper 1
H1N1
url http://journal.frontiersin.org/article/10.3389/fimmu.2018.00295/full
work_keys_str_mv AT susanlbaldwin improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT fanchihsu improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT nealvanhoeven improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT emilygage improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT briangranger improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT jeffreyaguderian improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT sashaelarsen improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT ericaclorenzo improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT laurahaynes improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT stevengreed improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT rheancoler improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT rheancoler improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
AT rheancoler improvedimmuneresponsesinyoungandagedmicewithadjuvantedvaccinesagainsth1n1influenzainfection
_version_ 1725742261906440192